[Clinical significance of the terminal complement complex in children with type I membranoproliferative glomerulonephritis].
Kobayashi
Yasuaki
Y
Division of Pediatrics, Ohtawara Red Cross Hospital, Tochigi, Japan.
Hasegawa
Osamu
O
Honda
Masataka
M
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D002648:Child; D015938:Complement Membrane Attack Complex / Q000032:analysis*; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D015938:Complement Membrane Attack Complex; D011239:Prednisolone; D008775:Methylprednisolone